Clinical Trials

Phase 2 Active not recruiting

117 enrolled

Dermatologic

Melanoma

NCT03568058 2026-03-24

Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers

Phase 1 Completed

25 enrolled 12 charts

Tumor-Agnostic

Neoplasms

NCT04943848 2026-03-17

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Phase 1 Recruiting

36 enrolled

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

Phase 2/3 Recruiting

120 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Gynecologic

Endometrial Neoplasms

NCT07090148 2026-03-11

Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Phase 1 Recruiting

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06114940 2026-03-05

PLUTO

Phase 2 Terminated

17 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

CNSEndocrineGenitourinary

40 enrolled

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

NCT03983057 2026-02-11

Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer

Phase 2 Completed

392 enrolled

Pancreatic Neoplasms

NCT05223231 2026-02-02

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

Phase 1/2 Completed

26 enrolled

Advanced Malignant Tumors

NCT02961101 2026-01-22

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Phase 1 Active not recruiting

250 enrolled

Neoplasms, Recurrence

NCT03891953 2026-01-21

Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

98 enrolled

BreastDermatologicHead & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms

NCT06468280 2026-01-21

ROSETTE

Phase 2 Recruiting

84 enrolled

Stomach Neoplasms

NCT06470971 2026-01-20

Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

Phase 2 Recruiting

40 enrolled

Phase 1/2 Active not recruiting

Advanced Malignant Solid Neoplasm

NCT05210413 2026-01-15

SPARTO

80 enrolled

Refractory or Recurrent Solid Tumor

NCT06265727 2026-01-08

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

348 enrolled

Phase 2 Active not recruiting

Solid Tumor, Adult

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

33 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT07318636 2026-01-06

NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC

Phase 1 Not yet recruiting

10 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04146298 2025-12-24

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

30 enrolled

Pancreatic Neoplasms

NCT04294160 2025-12-24

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

122 enrolled

Phase 3 Not yet recruiting

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT07277842 2025-12-11

PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer

382 enrolled

Locally Advanced Low Rectal Adenocarcinoma

NCT06493240 2025-11-25

NLCCRIT-LARC

Phase 2 Completed

30 enrolled

Phase 1 Active not recruiting

Locally Advanced Rectal Cancer

NCT05631899 2025-11-24

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

9 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT07245901 2025-11-24

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Phase 1/2 Not yet recruiting

60 enrolled

Solid Tumor

NCT02936102 2025-11-14

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1 Active not recruiting

154 enrolled

BreastSarcoma

Chordoma, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

NCT04058756 2025-10-07

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

120 enrolled

Phase 2 Active not recruiting

Advanced Solid Tumors

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

19 enrolled

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies